At Microomics Systems, we specialize in -omics technologies focused on microbiome analysis, including metagenomics, transcriptomics, and prokaryotic genomics. Our team of experts brings extensive experience in molecular biology, bioinformatics, and biostatistics, allowing us to deliver comprehensive and tailored solutions for every project.

Microomics provides a full-service analysis, managing every stage of the process with close attention to detail from start to finish. We operate not only as a sequencing and bioinformatics analysis company, but also as a CRO, with strong expertise in result validation through proprietary controls and pipelines.

Nanomol Technologies is both a Drug Delivery and a GMP certified Contract Analysis partner for pharmaceutical and biotech industries.

Our DELOS nanoformulation technology enables the development of  value-added medicines with enhanced efficacy, selectivity and reduced side-effects.

We provide value to companies who require appropriate characterization of critical quality attributes such as particle size, morphology and structural properties of both drug substance and drug products.

At Nostrum Biodiscovery, we aim to accelerate drug discovery, molecular design and engineering through computational technologies. We develop AI-driven molecular modeling technology and make the most of quantum mechanics and high-performance computing to provide faster, more cost-effective and accurate solutions for biotech and pharma companies. We help researchers and R&D teams tackle challenges across nucleic acids therapeutics, targeted protein degradation, small molecule drug discovery and antibody design, reducing the need for experimental validation while accelerating the development of innovative therapies. Our proprietary in silico screening and biophysical simulation platforms enable clients to design better drugs, optimize formulations, and streamline the development pipeline. In short, we bridge the gap between computation and experimental validation to accelerate smarter therapeutic development. With Nostrum, you design better, fail less, and move faster.

Organaid combines patient-derived 3D organoids with ImPheNet, our proprietary AI engine, to predict drug efficacy and toxicity before a compound reaches the clinic, reducing attrition, cutting timelines, and lowering development costs at the preclinical stage.

 We are currently producing central nervous system organoids and, from September onwards, we will scale to industrial-level production at the Parc Científic of Barcelona (Spain), expanding our portfolio to additional organ systems and regenerative medicine.

RidNova is a biopharmaceutical company dedicated to addressing health challenges and driving innovation in pharmaceuticals, biosimilars, and biologics, to improve patient outcomes. We specialise in formulation development, formulation consulting, analytical and commercial manufacturing, leveraging state-of-the-art technologies and extensive industry expertise. We offer comprehensive product and dossier development and formulation, regulatory & CMC consultancy, advisory services in complex formulation, biosimilars, biologicals, 505 b (2)/hybrid, differentiated, innovative, value-added formulations to Pharma, CDMO, small biotech/startups for formulation, as well as guidance on regulatory strategy. RidNova also provides services in IP, regulatory submissions, post-launch activities and strategic publication planning to support the successful introduction and positioning of pharmaceutical assets in the market.

VERSA Biomedical, before Specipig, is a pioneer Breeding and  Biomedical Research Centre focused on the pig model. We breed miniature  pigs and run in-vivo pig model preclinical studies for: - Medical  device, tissue regeneration and new materials development: prototype,  efficacy, biocompatibility, product knowledge, development and  scientific evidence studies to attract investment and to develop the  product. - Pharma preclinical development: efficacy, toxicology,  pharmacokinetic, tolerance and proof of concept studies. We are GLP  certified, have fully equipped surgery rooms and housing. Are experts on  the pig model and we run stress management trainings with the animals  to improve their welfare. We are at present working on the development  on an Onco-pig model for use in preclinical studies.  

● Versa Biomedical draws on Specipig's 13 years of experience  as a preclinical CRO dedicated to designing flexible and personalized  biomedical models. Thanks to this expertise, it will continue to offer innovative solutions to biomedical, pharmaceutical, biotechnology, and medical device companies.

● On its part, Specipig will focus on all activities related to the breeding and marketing of its own genetic line of miniature pigs, offering its services to other CROs.

● The goal of this strategic split is to enhance and reinforce the specialization of both companies,  in order to provide a better service tailored to the specific needs of  their clients. The differential value of Versa Biomedical + Specipig lies in the fact that they are two specialized companies in one.